Acute Respiratory Distress Syndrome News and Research RSS Feed - Acute Respiratory Distress Syndrome News and Research

Patients who survived life-threatening illness in ICU at increased risk for psychiatric symptoms

Patients who survived life-threatening illness in ICU at increased risk for psychiatric symptoms

Results of a multi-institutional national study of nearly 700 people who survived life-threatening illness with a stay in an intensive care unit (ICU) suggest that a substantial majority of them are at high risk for persistent depression, anxiety and post-traumatic stress disorder — especially if they are female, young and unemployed. [More]
Scientists develop new drug for life-threatening lung disease treatment

Scientists develop new drug for life-threatening lung disease treatment

Researchers are developing a new drug to treat life-threatening lung damage and breathing problems in people with severe infections like pneumonia, those undergoing certain cancer treatments and premature infants with underdeveloped, injury prone lungs. [More]
Seasonal trivalent influenza vaccination during pregnancy may guard against stillbirth

Seasonal trivalent influenza vaccination during pregnancy may guard against stillbirth

Seasonal influenza vaccination may guard against stillbirth, a new study published in Clinical Infectious Diseases and available online suggests. Researchers in Western Australia analyzed data from nearly 60,000 births that occurred during the southern hemisphere's 2012 and 2013 seasonal influenza epidemics, and found that women who received the trivalent influenza vaccine during pregnancy were 51 percent less likely to experience a stillbirth than unvaccinated mothers. [More]
Variations in Tie2 gene play significant role in patient responses to infections

Variations in Tie2 gene play significant role in patient responses to infections

Major infections such as influenza and bacterial sepsis kill millions of people each year, often resulting fro dangerous complications that impair the body's blood vessels. But the reasons why some patients experience these dramatic responses to infections -- and others don't -- have been unclear. [More]
Critically ill patients exposed to higher ozone levels more likely to develop ARDS

Critically ill patients exposed to higher ozone levels more likely to develop ARDS

Critically ill patients who are exposed to higher daily levels of ozone are more likely to develop acute respiratory disease syndrome (ARDS), according to a new study published online ahead of print in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine. [More]
CareFusion to display new respiratory solutions at AARC Congress

CareFusion to display new respiratory solutions at AARC Congress

CareFusion, a BD company, will be displaying new respiratory solutions that are designed to put patients first, whether ventilated or breathing on their own, at the American Association for Respiratory Care Congress being held Nov. 7-10 in Tampa, Fla. [More]
Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

"We are pleased to receive positive CHMP opinions for Kyprolis and BLINCYTO as this is an important step in providing new treatment options for patients in Europe with rare forms of cancer," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. [More]
Potential new treatment for sepsis and ARDS

Potential new treatment for sepsis and ARDS

Scientists at Queen's University Belfast are developing a potential revolutionary new treatment for Sepsis and Acute Respiratory Distress Syndrome (ARDS), which are among the leading causes of death in hospitalised patients in the UK. [More]
FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

Boehringer Ingelheim today announced that both the U.S. Food and Drug Administration and the European Medicines Agency have accepted filing applications for afatinib for the treatment of patients with advanced squamous cell carcinoma (SCC) of the lung progressing after treatment with first-line chemotherapy. [More]
McMaster research shows benefits of corticosteroid therapy for patients with pneumonia

McMaster research shows benefits of corticosteroid therapy for patients with pneumonia

McMaster University research, published online today by the Annals of Internal Medicine, has demonstrated the benefits of corticosteroid therapy for one of the most common serious medical conditions. [More]
ZEVALIN drug now available to non-Hodgkin's lymphoma patients in Hong Kong

ZEVALIN drug now available to non-Hodgkin's lymphoma patients in Hong Kong

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announces that ZEVALIN is now available at hospitals in Hong Kong to patients with indicated non-Hodgkin's lymphoma (NHL), including at Hong Kong Sanatorium & Hospital. [More]
The Lancet publishes new Seminar on MERS

The Lancet publishes new Seminar on MERS

Middle East respiratory syndrome (MERS) has recently returned to the headlines as new cases have been exported to Korea and China. Experts are concerned that MERS cases continued to be detected in Saudi Arabia throughout the past year, and there appears to be little reduction in the number of cases since its first discovery three years ago. As the month of Ramadan approaches, with 1 million pilgrims expected to arrive in Saudi Arabia in June and July 2015, MERS remains a threat to global health security. [More]
ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® [More]
ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® [More]
Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib, in patients with advanced squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy. Treatment with afatinib significantly reduced the risk of death by 19%, extending the survival of patients to a median of 7.9 months compared to 6.8 months on erlotinib. [More]
Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. Food and Drug Administration (FDA) approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent (IMiD). [More]
New study describes way to regenerate lung tissue after injury

New study describes way to regenerate lung tissue after injury

A new collaborative study describes a way that lung tissue can regenerate after injury. The team found that lung tissue has more dexterity in repairing tissue than once thought. [More]
Rare genetic mutation explains why flu can kill in rare cases

Rare genetic mutation explains why flu can kill in rare cases

Nobody likes getting the flu, but for some people, fluids and rest aren't enough. A small number of children who catch the influenza virus fall so ill they end up in the hospital — perhaps needing ventilators to breathe — even while their family and friends recover easily. New research by Rockefeller University scientists, published March 26 in Science, helps explain why: a rare genetic mutation. [More]
Early mobility therapy improves outcomes of patients with acute respiratory distress syndrome

Early mobility therapy improves outcomes of patients with acute respiratory distress syndrome

Acute respiratory distress syndrome (ARDS) is a life-threatening lung condition that affects approximately 200,000 people a year in the United States and has a higher mortality rate than breast and prostate cancer combined. The condition most often occurs in people who are critically ill or who have significant injuries; those who do survive it often experience profound skeletal muscle weakness. [More]
Corticosteroids decrease treatment failure among patients with community-acquired pneumonia

Corticosteroids decrease treatment failure among patients with community-acquired pneumonia

Among patients with severe community-acquired pneumonia and high initial inflammatory response, the use of the corticosteroid methylprednisolone decreased treatment failure, compared with placebo, according to a study in the February 17 issue of JAMA. [More]
Advertisement
Advertisement